Among 124,777 UK Biobank participants followed for 12 years, highest versus lowest adherence to the DASH diet was associated with an 11% reduction in incident heart failure or HF-related death (aHR 0.89, 95% CI 0.79–1.00) after adjusting for obesity, hypertension, and type 2 diabetes. The Mediterranean diet showed a comparable 12% unadjusted risk reduction, but this association was attenuated to non-significance once cardiometabolic mediators were controlled. PUFA intake — a component not captured in standard Med or DASH scoring — independently reduced HF risk by 13% (HR 0.87).
The mechanistic divergence between these two diets is the most clinically instructive element here. The Mediterranean diet's association with HF risk appears substantially mediated through improvements in obesity, hypertension, and diabetes — essentially downstream metabolic benefits. DASH, by contrast, retains an independent signal, consistent with its direct blood-pressure-lowering mechanisms via sodium restriction and potassium-rich foods, which operate on cardiac remodeling pathways beyond simple metabolic control. This distinction matters for clinical recommendations: patients already managing cardiometabolic conditions may derive unique additional benefit from DASH-specific features rather than Mediterranean adherence alone.
The PUFA finding is genuinely novel and hypothesis-generating, echoing emerging omega-3 cardiac data but requiring dedicated investigation. Limitations are notable: dietary recall introduces measurement error, observational design precludes causality, and the relatively healthy UK Biobank cohort limits generalizability to high-risk populations. Overall, this is a confirmatory-with-nuance study — incrementally important for dietary counseling in cardiology practice.
